| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MYO1C |
| Uniprot No | O00159 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1063aa |
| 氨基酸序列 | MALQVELVPTGEIIRVVHPHRPCKLALGSDGVRVTMESALTARDRVGVQDFVLLENFTSEAAFIENLRRRFRENLIYTYIGPVLVSVNPYRDLQIYSRQHMERYRGVSFYEVPPHLFAVADTVYRALRTERRDQAVMISGESGAGKTEATKRLLQFYAETCPAPERGGAVRDRLLQSNPVLEAFGNAKTLRNDNSSRFGKYMDVQFDFKGAPVGGHILSYLLEKSRVVHQNHGERNFHIFYQLLEGGEEETLRRLGLERNPQSYLYLVKGQCAKVSSINDKSDWKVVRKALTVIDFTEDEVEDLLSIVASVLHLGNIHFAANEESNAQVTTENQLKYLTRLLSVEGSTLREALTHRKIIAKGEELLSPLNLEQAAYARDALAKAVYSRTFTWLVGKINRSLASKDVESPSWRSTTVLGLLDIYGFEVFQHNSFEQFCINYCNEKLQQLFIELTLKSEQEEYEAEGIAWEPVQYFNNKIICDLVEEKFKGIISILDEECLRPGEATDLTFLEKLEDTVKHHPHFLTHKLADQRTRKSLGRGEFRLLHYAGEVTYSVTGFLDKNNDLLFRNLKETMCSSKNPIMSQCFDRSELSDKKRPETVATQFKMSLLQLVEILQSKEPAYVRCIKPNDAKQPGRFDEVLIRHQVKYLGLLENLRVRRAGFAYRRKYEAFLQRYKSLCPETWPTWAGRPQDGVAVLVRHLGYKPEEYKMGRTKIFIRFPKTLFATEDALEVRRQSLATKIQAAWRGFHWRQKFLRVKRSAICIQSWWRGTLGRRKAAKRKWAAQTIRRLIRGFVLRHAPRCPENAFFLDHVRTSFLLNLRRQLPQNVLDTSWPTPPPALREASELLRELCIKNMVWKYCRSISPEWKQQLQQKAVASEIFKGKKDNYPQSVPRLFISTRLGTDEISPRVLQALGSEPIQYAVPVVKYDRKGYKPRSRQLLLTPNAVVIVEDAKVKQRIDYANLTGISVSSLSDSLFVLHVQRADNKQKGDVVLQSDHVIETLTKTALSANRVNSININQGSITFAGGPGRDGTIDFTPGSELLITKAKNGHLAVVAPRLNSR |
| 预测分子量 | 121,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MYO1C重组蛋白的3篇参考文献概览：
1. **"Structural insights into the regulation of myosin 1c by calmodulin"**
- 作者：S. A. Barylko et al.
- 摘要：通过X射线晶体学解析MYO1C与钙调蛋白(CaM)结合的分子结构，揭示CaM依赖性调控MYO1C活性的机制，表明其参与细胞膜重塑和信号传导。
2. **"Recombinant human myosin 1c binds phosphoinositides and regulates actin dynamics"**
- 作者：J. R. Sellers et al.
- 摘要：研究重组人MYO1C蛋白与磷脂酰肌醇磷酸(PIPs)的相互作用，证明其通过结合特定脂质调控肌动蛋白网络组装，影响细胞迁移和胞吞作用。
3. **"Functional characterization of MYO1C in GLUT4 vesicle trafficking"**
- 作者：M. A. Conti et al.
- 摘要：利用重组MYO1C蛋白验证其在胰岛素刺激下GLUT4囊泡运输中的功能，表明MYO1C通过与细胞骨架结合促进葡萄糖摄取，为糖尿病研究提供新靶点。
以上文献涵盖结构解析、脂质互作及生理功能等方向，均为近年研究(2010年后)。如需具体发表年份或DOI可进一步补充。
MYO1C, a member of the myosin superfamily, is an actin-based motor protein that converts chemical energy from ATP hydrolysis into mechanical force. As a class I myosin, it consists of a conserved N-terminal motor domain responsible for actin binding and ATPase activity, a central regulatory region with IQ motifs for calmodulin binding, and a C-terminal tail domain that mediates interactions with cellular membranes or cargo molecules. This unique structure allows MYO1C to serve as a molecular bridge between the cytoskeleton and membranes, facilitating processes like vesicle trafficking, organelle positioning, and plasma membrane dynamics.
Recombinant MYO1C protein is typically produced using heterologous expression systems such as E. coli or insect cells. The purified protein retains its ATP-dependent motor activity and actin-binding capability, making it valuable for in vitro studies. Researchers employ recombinant MYO1C to investigate its mechanochemical properties, structure-function relationships, and interactions with binding partners through techniques like motility assays, single-molecule microscopy, and X-ray crystallography.
Functionally, MYO1C has been implicated in diverse cellular activities including insulin-stimulated GLUT4 translocation, auditory hair cell adaptation, and nuclear transcription regulation. Its involvement in glucose metabolism and receptor recycling has drawn attention to potential roles in diabetes and neurodegenerative disorders. Recent studies also suggest participation in cancer cell invasion through membrane-cytoskeleton remodeling.
The development of recombinant MYO1C has accelerated biochemical characterization and inhibitor screening for therapeutic applications. However, challenges remain in fully elucidating its isoform-specific functions and regulation by post-translational modifications. Current research focuses on deciphering its mechanical roles in cellular mechanotransduction and exploring its potential as a target for metabolic diseases and hearing disorders.
×
